韩国ABL生物公司从Eli Lilly公司获得55M美元,用于联合治疗开发,潜在价值高达2.6B美元。 South Korea’s ABL Bio gains $55M from Eli Lilly for joint therapy development, with up to $2.6B in potential value.

韩国一家生物技术公司ABL Bio已经从Eli Lilly那里获得5 500万美元,其中包括一笔4 000万美元的预付付款和1 500万美元的股本,这是根据其Grabody平台合作协议获得的。 ABL Bio, a South Korean biotech firm, has secured $55 million from Eli Lilly, including a $40 million upfront payment and $15 million in equity, under a collaboration agreement for its Grabody platform. 这项价值高达26亿美元的交易,使得能够以各种方式共同发展多种疗法。 The deal, valued up to $2.6 billion, enables joint development of multiple therapies across various modalities. ABL Bio将利用这些资金向肥胖症和肌肉紊乱症等高需求地区扩展,推进双特定免疫-肿瘤综合疗法,并发展下一代抗体药物聚合。 ABL Bio will use the funds to expand into high-unmet-need areas like obesity and muscle disorders, advance bispecific immuno-oncology combination therapies, and develop next-generation antibody-drug conjugates. 该公司正在执行八个临床方案,包括ABL001(FDA快车道指认)和ABL111,这两个方案在第一阶段b试验中显示出有希望的结果。 The company has eight clinical programs underway, including ABL001 (with FDA Fast Track designation) and ABL111, which showed promising results in a Phase 1b trial. 交易是在完成监管审查之后进行的。 The transaction followed completion of regulatory reviews.